Author

N. Vemalapally

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2 Assay:bulk RNA-seq· 1 Organism:human· 1 Organism:mouse· 1 Assay:organoid / primary culture· 1 Assay:proteomics· 1

Frequent Co-Authors

A. R. Tipton· 2 shared I. S. Hagemann· 2 shared R. Bose· 2 shared S. Li· 2 shared A. Iliuk· 1 shared B. Zhou· 1 shared C. X. Ma· 1 shared C.-Y. Lin· 1 shared

Activity by Year

2022-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 36 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

A. R. Tipton

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Neratinib Synergizes with Trastuzumab Antibody Drug Conjugate or with Vinorelbine to Treat HER2 Mutated Breast Cancer Patient Derived Xenografts and Organoids.

S. Li, T. M. Primeau, M. K. Highkin, S. L. Pratt, A. R. Tipton, N. Vemalapally, J. D. Monsey, Y. Tao, J. Luo, I. S. Hagemann, C.-Y. Lin, L. D. Eli, C. X. Ma, R. Bose

The paper tests neratinib combinations with T-DM1 and vinorelbine in HER2 mutated breast cancer PDX models and organoids, finding synergistic effects that could inform clinical trials.

bioRxiv · Dec 19, 2023 · PreprintCancer Biology

Breast cancer mutations HER2 V777L and PIK3CA H1047R activate the p21/CDK4/6/Cyclin D1 axis driving tumorigenesis and drug resistance.

X. Cheng, Y. Sun, M. Highkin, N. Vemalapally, X. Jin, B. Zhou, J. L. Prior, A. R. Tipton, S. Li, A. Iliuk, S. Achilefu, I. S. Hagemann, J. R. Edwards, R. Bose

This study investigates how HER2 V777L and PIK3CA H1047R mutations drive breast cancer tumorigenesis and drug resistance, showing effective combination therapies.

bioRxiv · Nov 9, 2022 · PreprintCancer Biology